Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats

Drug Metabolism and Disposition

Volumn 39, Issue 3, 2011, Pages 419-425

  Hu, Nan ^a   Xie, Shanshan ^a,b   Liu, Li ^a   Wang, Xinting ^a   Pan, Xian ^a   Chen, Guanming ^a   Zhang, Lulu ^a   Liu, Haiyan ^a   Liu, Xiang ^a   Liu, Xiaodong ^a   Xie, Lin ^a   Wang, Guangji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANCHANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; NORVERAPAMIL; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; IN VITRO STUDY; INTESTINE; LIVER MICROSOME; MALE; MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES;

ADMINISTRATION, ORAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 CYP3A; DIABETES MELLITUS, EXPERIMENTAL; HALF-LIFE; INJECTIONS, INTRAVENOUS; INTESTINE, SMALL; MALE; MEMBRANE PROTEINS; METABOLIC CLEARANCE RATE; MICROSOMES; MICROSOMES, LIVER; ORGAN SPECIFICITY; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; VERAPAMIL;

RATTUS;

EID: 79951909146     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035642     Document Type: Article

References (38)

1. Abdelmegeed MA, Carruthers NJ, Woodcroft KJ, Kim SK, and Novak RF (2005) Acetoacetate induces CYP2E1 protein and suppresses CYP2E1 mRNA in primary cultured rat hepatocytes. J Pharmacol Exp Ther 315:203-213.
2. Borbás T, Benko B, Dalmadi B, Szabó I, and Tihanyi K (2006) Insulin in flavin-containing monooxygenase regulation. Flavin-containing monooxygenase and cytochrome P450 activities in experimental diabetes. Eur J Pharm Sci 28:51-58.
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
4. Brunner LJ, Iyer LV, Vadiei K, Weaver WV, and Luke DR (1989) Cyclosporine pharmacokinetics and effect in the type I diabetic rat model. Eur J Drug Metab Pharmacokinet 14:287-292.
5. Bruyère A, Declevès X, Bouzom F, Proust L, Martinet M, Walther B, and Parmentier Y (2009) Development of an optimized procedure for the preparation of rat intestinal microsomes: comparison of hepatic and intestinal microsomal cytochrome P450 enzyme activities in two rat strains. Xenobiotica 39:22-32.
6. Carnovale CE, Marinelli RA, and Rodríguez Garay EA (1986) Bile flow decrease and altered bile composition in streptozotocin-treated rats. Biochem Pharmacol 35:2625-2628.
7. Choi JS and Burm JP (2008) Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats. Arch Pharm Res 31:1200-1204.
8. Fromm MF, Dilger K, Busse D, Kroemer HK, Eichelbaum M, and Klotz U (1998) Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction. Br J Clin Pharmacol 45:247-255.
9. García Donaire JA and Ruilope LM (2007) Trandolapril/verapamil combination in hypertensive diabetic patients. Vasc Health Risk Manag 3:77-82.
10. Hanada K, Ikemi Y, Kukita K, Mihara K, and Ogata H (2008) Stereoselective first-pass metabolism of verapamil in the small intestine and liver in rats. Drug Metab Dispos 36:2037-2042.
11. Ioannides C, Barnett CR, Irizar A, and Flatt PR (1996) Expression of cytochrome P450 protein in disease, in Cytochrome P450. Metabolic and Toxicological Aspects (Ioannides C, ed) pp 301-327, CRC Press, Boca Raton, FL.
12. Iwatsubo T, Suzuki H, and Sugiyama Y (1997) Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. J Pharmacol Exp Ther 283:462-469.
13. Kim YC, Lee AK, Lee JH, Lee I, Lee DC, Kim SH, Kim SG, and Lee MG (2005a) Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci 26:114-123.
14. Kim YC, Lee JH, Kim SH, and Lee MG (2005b) Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus. Antimicrob Agents Chemother 49: 2528-2532.
15. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, and Eichelbaum M (1993) Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 348:332-337.
16. Lee JH and Lee MG (2008) Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin. Pharm Res 25:1915-1924.
17. Lee JH, Yang SH, Oh JM, and Lee MG (2010) Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. J Pharm Pharmacol 62:1-23.
18. Lewis DFV (1996) Cytochrome P450: Structure, Function and Mechanism, Taylor & Francis, London.
19. Lin JH, Chiba M, and Baillie TA (1999) Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135-158.
20. Liu L, Deng YX, Liang Y, Pang XY, Liu XD, Liu YW, Yang JS, Xie L, and Wang GJ (2010) Increased oral AUC of baicalin in streptozotocin-induced diabetic rats due to the increased activity of intestinal beta-glucuronidase. Planta Med 76:70-75.
21. McTavish D and Sorkin EM (1989) Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drug 38:19-76.
22. Mitschke D, Reichel A, Fricker G, and Moenning U (2008) Characterization of cytochrome P450 protein expression along the entire length of the intestine of male and female rats. Drug Metab Dispos 36:1039-1045.
23. Nadai M, Yoshizumi H, Kuzuya T, Hasegawa T, Johno I, and Kitazawa S (1990) Effect of diabetes on disposition and renal handling of cefazolin in rats. Drug Metab Dispos 18:565-570.
24. Ogata M, Iizuka Y, Murata R, and Hikichi N (1996) Effect of streptozotocin-induced diabetes on cyclosporin A disposition in rats. Biol Pharm Bull 19:1586-1590.
25. Price VF and Jollow DJ (1986) Strain differences in susceptibility of normal and diabetic rats to acetaminophen hepatotoxicity. Biochem Pharmacol 35:687-695.
26. Sato H, Terasaki T, Okumura K, and Tsuji A (1991) Effect of receptor up-regulation on insulin pharmacokinetics in streptozotocin-treated diabetic rats. Pharm Res 8:563-569.
27. Schomerus M, Spiegelhalder B, Stieren B, and Eichelbaum M (1976) Physiological disposition of verapamil in man. Cardiovasc Res 10:605-612.
28. Shimojo N (1994) Cytochrome P450 changes in rats with streptozocin-induced diabetes. Int J Biochem 26:1261-1268.
29. Shimojo N, Ishizaki T, Imaoka S, Funae Y, Fujii S, and Okuda K (1993) Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem Pharmacol 46:621-627.
30. Thummel KE and Schenkman JB (1990) Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat. Mol Pharmacol 37:119-129.
31. Tracy TS, Korzekwa KR, Gonzalez FJ, and Wainer IW (1999) Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 47:545-552.
32. Watkins JB 3rd and Sherman SE (1992) Long-term diabetes alters the hepatobiliary clearance of acetaminophen, bilirubin and digoxin. J Pharmacol Exp Ther 260:1337-1343.
33. Woodcock BG, Rietbrock I, Vöhringer HF, and Rietbrock N (1981) Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships. Clin Pharmacol Ther 29:27-34.
34. Woodcroft KJ, Hafner MS, and Novak RF (2002) Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology 35:263-273.
35. Xie SS, Hu N, Jing XY, Liu XD, Xie L, Wang GJ, and Liu CH (2010) Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats. J Pharm Pharmacol 62:440-447.
36. Yamazoe Y, Murayama N, Shimada M, Yamauchi K, and Kato R (1989) Cytochrome P450 in livers of diabetic rats: regulation by growth hormone and insulin. Arch Biochem Biophys 268:567-575.
37. Yu S, Yu Y, Liu L, Wang X, Lu S, Liang Y, Liu X, Xie L, and Wang G (2010a) Increased plasma exposures of five protoberberine alkaloids from Coptidis Rhizoma in streptozotocin-induced diabetic rats: is P-GP involved? Planta Med 76:876-881.
38. Yu Y, Liu L, Wang X, Liu X, Liu X, Xie L, and Wang G (2010b) Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem Pharmacol 79:1000-1006.